- Home
- ACIU vs TWN Comparison
ACIU vs TWN Comparison
Compare ACIU & TWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- TWN
- Stock Information
- Founded
- ACIU 2003
- TWN 1986
- Country
- ACIU Switzerland
- TWN Hong Kong
- Employees
- ACIU N/A
- TWN N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- TWN Trusts Except Educational Religious and Charitable
- Sector
- ACIU Health Care
- TWN Finance
- Exchange
- ACIU Nasdaq
- TWN Nasdaq
- Market Cap
- ACIU 332.4M
- TWN 306.6M
- IPO Year
- ACIU 2016
- TWN N/A
- Fundamental
- Price
- ACIU $2.68
- TWN $45.79
- Analyst Decision
- ACIU Strong Buy
- TWN
- Analyst Count
- ACIU 2
- TWN 0
- Target Price
- ACIU $12.00
- TWN N/A
- AVG Volume (30 Days)
- ACIU 134.5K
- TWN 20.1K
- Earning Date
- ACIU 11-05-2024
- TWN 01-01-0001
- Dividend Yield
- ACIU N/A
- TWN 1.10%
- EPS Growth
- ACIU N/A
- TWN N/A
- EPS
- ACIU N/A
- TWN N/A
- Revenue
- ACIU $48,505,404.00
- TWN N/A
- Revenue This Year
- ACIU $85.33
- TWN N/A
- Revenue Next Year
- ACIU $80.69
- TWN N/A
- P/E Ratio
- ACIU N/A
- TWN N/A
- Revenue Growth
- ACIU 4097200.00
- TWN N/A
- 52 Week Low
- ACIU $2.25
- TWN $25.22
- 52 Week High
- ACIU $5.14
- TWN $41.51
- Technical
- Relative Strength Index (RSI)
- ACIU 27.49
- TWN 53.99
- Support Level
- ACIU $2.62
- TWN $44.67
- Resistance Level
- ACIU $3.02
- TWN $47.24
- Average True Range (ATR)
- ACIU 0.13
- TWN 1.21
- MACD
- ACIU -0.05
- TWN 0.13
- Stochastic Oscillator
- ACIU 9.52
- TWN 50.63
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About TWN Taiwan Fund Inc. (The)
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.